{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-098059","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2024-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.023661+00:00","generated_at":"2026-05-31T05:57:02.691644+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ArriVent: firmonertinib shows 81.8% ORR in EGFR PACC mutant NSCLC Phase 1b data","bullets":["81.8% ORR and 63.6% confirmed ORR by BICR at 240mg dose in first-line EGFR PACC mutant NSCLC.","46.2% confirmed CNS ORR (6/13) in patients with brain metastases at baseline.","Median duration of response not reached; 90.9% (20/22) of confirmed responders remain on study.","No Grade 4/5 TRAEs or treatment discontinuations due to TRAEs; safety consistent with prior data.","Data presented at WCLC 2024; ArriVent plans virtual webinar on September 9, 2024 at 4:30pm ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-098059","json":"https://secwatch.observer/filing/0001104659-24-098059.json","markdown":"https://secwatch.observer/filing/0001104659-24-098059.md","text":"https://secwatch.observer/filing/0001104659-24-098059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465924098059/0001104659-24-098059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465924098059/tm2423588d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:57:02.691644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}